Does BGB-11417 Cause Off label use? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Off label use have been filed in association with BGB-11417. This represents 4.9% of all adverse event reports for BGB-11417.
6
Reports of Off label use with BGB-11417
4.9%
of all BGB-11417 reports
3
Deaths
6
Hospitalizations
How Dangerous Is Off label use From BGB-11417?
Of the 6 reports, 3 (50.0%) resulted in death, 6 (100.0%) required hospitalization, and 2 (33.3%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BGB-11417. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does BGB-11417 Cause?
Febrile neutropenia (16)
Death (10)
Neutropenic sepsis (10)
Acute myeloid leukaemia (9)
Pneumonia (7)
Covid-19 (5)
Pyrexia (5)
Sepsis (5)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which BGB-11417 Alternatives Have Lower Off label use Risk?
BGB-11417 vs BICALUTAMIDE
BGB-11417 vs BICTEGRAVIR
BGB-11417 vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
BGB-11417 vs BIFIDOBACTERIUM LONGUM
BGB-11417 vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS